Cite
HARVARD Citation
Davies, M. et al. (n.d.). Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet oncology. 18 (7), pp. 863-873. [Online].